In the vascular lumen, the main function of the serine protease tissue-type plasminogen activator (tPA) is activation of the zymogen plasminogen to plasmin, and subsequent degradation of fibrin clots.
(single-chain tPA vs. two-chain tPA). 19 Recently, we proposed an alternative explanation, suggesting that the neurovascular events regulated by tPA might provide a unifying pathway for many of the pleiotropic effects of tPA. 20 We reasoned that instead of tPA directly performing all these diverse functions in the CNS, it might be that tPA's role in regulating cerebrovascular integrity, and thereby parenchymal homeostasis, could indirectly affect events such as neuronal-signaling pathways and excitotoxicity through loss of precise control of the extracellular environment. In this review, we will summarize what is known about the role of tPA in the CNS during physiology and disease in light of this cerebrovascular regulatory theory.
The Neurovascular Unit and the Blood-Brain Barrier
The cerebrovascular bed is unique in that normal CNS function requires a highly regulated extracellular environment to keep the concentrations of most molecules within a very narrow range. 21 Cerebrovascular homeostasis is maintained by the BBB, which forms a mechanical and functional barrier between the systemic circulation and the CNS that tightly controls trafficking of substances between the blood and the CNS. 22 The barrier properties are established by the brain endothelial cells, but it is widely recognized that the other cells in the neurovascular unit (NVU), including perivascular astrocytes in particular as well as vascular mural cells (vascular smooth muscle cells and pericytes) and neurons, all work together in a coordinated way to regulate the extracellular environment of the brain parenchyma (►Fig. 1). 20, 21, 23, 24 Thus, the interaction between neurons, astrocytes, and endothelial cells plays a central role, coupling energy supply and changes in the CNS extracellular environment with neuronal activity.
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Is tPA-Mediated Regulation of Neurovascular Responses the Initial Event Directing Later Responses in the CNS?
It is well established that cerebrovascular responses to neuronal activity are critical for maintaining parenchymal homeostasis through three closely linked and related effects:
(1) neurovascular coupling, which refers to increases in cerebral blood flow in response to neuronal activity; (2) neurobarrier coupling, which refers to changes in transport or the movement of molecules across the BBB; and (3) neurometabolic coupling, which refers to changes in local metabolic factors, such as glucose and lactate, in response to neuronal activity. 28 The reports showing that tPA promotes neurovascular, 7 neurobarrier, 14 and possibly neurometabolic coupling 29 thus suggest that under physiologic conditions, tPA is released into the NVU in response to neuronal activity, where it exerts these neurovascular effects to accommodate the increased energy demand incurred by the increased firing rates occurring during routine processing in the neocortex. However, during pathologic conditions, this is exaggerated leading to disproportionate opening of the BBB, which results in extravasation of harmful blood-borne substances into the CNS and the subsequent loss of the tight regulation of the CNS extracellular environment. Based on this, we hypothesize that the neurovascular events regulated by tPA could provide a unifying pathway for many of the pleiotropic effects of tPA in the CNS. For example, studies have suggested that a primary role of tPA in the CNS is direct regulation of neuronal activity through its action on the N-methyl-D-aspartate (NMDA) receptor and neuronal calcium signaling. 10, 30, 31 However, as the concentration of glutamate is 25-to 200-fold higher in plasma than in the CNS extracellular fluids, 32 it is conceivable that tPA-induced changes in BBB permeability could overwhelm the astrocyte-mediated glutamate shuttle resulting in the buildup of extracellular glutamate, 33 which in turn could promote dysregulation of the NMDA-signaling pathways and lead to excitotoxicity. 9 Thus, we suggest a possible common pathway for tPA permitting modulation of CNS function through the regulation of the NVU.
Physiologic Roles of tPA in the CNS
Our understanding about the physiologic role of tPA in the CNS is still very limited and most of our knowledge is based on studies utilizing genetically modified mice in various experimental models of disease as well as in vitro systems. However, in recent years, significant efforts and advancements have been made to delineate the function and mechanism of action of tPA in the CNS (summarized in ►Table 1).
Expression, Regulation, and Downstream Mediators
Expression tPA is widely expressed in the CNS, but until recently little has been reported on its cellular and subcellular distribution in vivo in healthy brain. Among the highest expression of tPA in the murine, CNS is seen within the vascular endothelial cells 34 ; however, it is believed that this source of tPA is nearly exclusively released into the blood stream upon stimuli and not into the parenchyma of the CNS. 35 High expression of tPA in the murine brain has also been reported in the cortex, amygdala, and the mossy fibers of the hippocampus, 36, 37 42 A recent study claims that the neuronal expression of tPA is restricted to a subset of excitatory neurons in mice and rats (after blockage of axodendritic transport) 41 ; however, this is not supported by our own findings, indicating that tPA is also expressed in a subset of perivascular interneurons in the naive murine 
Downstream Mediators
The mechanism by which tPA exerts its actions in the CNS is controversial. Both plasminogen-dependent and plasminogenindependent pathways have been postulated to act through several potential downstream mediators in the CNS, including matrix metalloprotease 9 (MMP-9), 59 activated protein C, including neurotoxic and neuroprotective roles as well as regulation of cerebrovascular permeability (discussed in further detail later).
Function in the Central Nervous System
To investigate the role of tPA in the CNS, many studies have utilized mice where the gene for tPA, Plat, has been deleted.
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These mice have been said to express the nonproteolytic domains of tPA with the potential to influence experimental outcomes 70 ; however, there is no experimental evidence in the literature supporting this claim. It has also been reported that the existing strain of tPA-deficient mice (tPA À/À ) do retain significant segments of 129 DNA associated with the Plat allele, even after extensive backcrossing onto C57BL/6J background. 71 This study also showed that this region of chromosome 8 carries a significant number of mutations unique to the 129 strain that cosegregate with the Plat allele, including several potential null mutations. This may confound the interpretation of experiments performed utilizing the original tPA À/À mice, 69 and is why a novel "passenger mutation"-free tPA-deficient mouse strain (tPA À/À NIH ) was generated as a useful community resource for further exploration of tPA function in physiology and disease.
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Central Nervous System Development
Very little is known about the role of tPA in CNS development, although genetic deletion studies indicate that tPA does not play an essential role during embryonic development.
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Expression studies in the developing mouse CNS have shown that tPA is synthesized by a variety of neuronal cells, with the highest expression reported in areas of extensive neuronal migration and tissue remodeling. 72 Based on these findings, it has been hypothesized that tPA facilitates neuronal migration or neurite outgrowth through degradation of cell-cell or cellmatrix adhesions. Since then, several studies, mainly in vitro cell culture experiments and also some in vivo studies, have been performed, supporting a role for tPA in neuronal remodeling and migration during CNS development. For example, tPA was found to be released at the neuronal growth cone, 73 and to mediate neurite outgrowth and remodeling.
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Furthermore, it was shown that migration of cerebellar granule neurons is perturbed in tPA À/À mice. 75 With regard to the BBB hypothesis, it is tempting to speculate that increased metabolic demand during neuronal migration might lead to tPA-mediated changes in neurovascular, and/ or neurometabolic, coupling responses. The tPA À/À mice were recently reported to display congenital brain defects including abnormal cerebrovascularization, indicating a previously unrecognized role of tPA in cerebrovascular development. 76 Interestingly, the tPA À/À mice were also found to display mild cerebral ventricular malformations, a feature previously associated with ablation of PDGF-CC, 77 thereby providing a potential in vivo link between tPA and PDGF signaling in CNS development. However, considering the novel report of the "passenger mutations" in these tPA À/À mice, it will be interesting to determine whether these congenital cerebrovascular and ventricular abnormalities are a true effect of tPA ablation also in the novel tPA À/À NIH strain. 71 If so, it will be interesting to determine whether this is a plasminogen-dependent or plasminogen-independent process through studies in plasminogen-deficient mice. It is interesting in this regard that obstructive hydrocephalus, associated with cerebroventricular enlargement, has been reported to be associated with plasminogen deficiency in humans. 78 It should be noted that these congenital defects might have unforeseen effects on the experimental outcome and thus needs to be taken into account when interpreting data achieved utilizing genetically modified mice.
Adult Central Nervous System Physiology
Learning and Memory
The idea that tPA is involved in the process of learning and memory came from the findings that tPA was highly expressed in the mossy fibers of the hippocampus and that neuronal activity induced mRNA expression of tPA in hippocampal pyramidal neurons during late-phase long-term potentiation (L-LTP).
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L-LTP is a well-studied model system of learning 79 and has been shown to be significantly decreased in tPA À/À mice. The underlying mechanism by which tPA might facilitate L-LTP has been shown to be mediated by LRP, 87 potentially via plasmin-mediated cleavage of pro-BDNF to the mature form of BDNF. 63 Interestingly though, L-LTP has been shown to be associated with increased BBB permeability 88 and the large pyramidal neurons within the hippocampus are known to have particularly high metabolic demand, thus making them especially sensitive to damage from a variety of environmental and biological insults. 89 Thus, in line with our hypothesis, it might be that tPA-induced changes in the NVU and the subsequent increase in cerebrovascular permeability during learning, through an LRP-dependent process, lead to altered parenchymal homeostasis which in turn promotes cleavage of pro-BDNF.
Neurovascular and Neurometabolic Coupling
Local cerebral blood flow increases rapidly in response to neuronal activity, a phenomenon termed "functional hyperemia" or "neurovascular coupling." This is believed to be critical for the maintenance of substrate and energy supply to the activated neurons as well as for clearance of metabolic by-products. 22 Although the process of neurovascular coupling is still not completely understood, perivascular astrocytes and various vasoactive mediators, including tPA, 7 have been proposed to be of importance. 28, 96 Using in vitro neuronal cultures under conditions of oxygen-glucose deprivation, it was shown that tPA, via a plasminogen-independent mechanism, increases neuronal uptake of glucose through induction of the glucose transporter GLUT3. Although intriguing, and in line with the idea that tPA facilitates neuronal function through coupling energy supply to demand, this needs to be confirmed in vivo, in nonpathologic conditions.
Vascular Permeability
The first indications that tPA plays a role in the regulation of vascular permeability came from animal studies of embolic stroke, where thrombolytic treatment with tPA was associated with evidence of increased vascular permeability. 97, 98 Since then, the association of tPA with the NVU and its correlation with BBB regulation has been well established, although the mechanism underlying this capacity of tPA remains controversial. 18 Some reports have suggested a plasmin-independent role for tPA, 14,15 whereas others have reported tPA-mediated plasmin generation as crucial for tPA activity on the BBB.
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Nevertheless, tPA's action on the BBB in mice has been shown to require interaction with the CNS side of the NVU, as tPA administered intravenously in unchallenged wild-type mice does not elicit opening of the BBB, whereas tPA administered on the CNS side of the NVU does.
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Our previous data show that PDGF-CC is acting directly downstream of tPA in the CNS, where it regulates BBB integrity through PDGF-receptor-α (PDGFR-α) signaling on perivascular astrocytes (►Fig. 2B).
15 PDGF-CC is expressed as a latent factor that is cleaved by tPA in a plasmin-independent manner to generate active PDGF-CC capable of binding PDGFR-α. 64 Injection of active PDGF-CC protein into the CSF of mice was reported, like tPA, to rapidly increase BBB permeability and neutralizing antibodies against PDGF-CCinhibited tPA-induced opening of the BBB. 15 No gross changes of vascular structures were reported within this time frame, even though the extent of Evan's blue extravasation into the brain parenchyma was significant, suggesting that the activation of PDGF-CC/PDGFR-α may represent a regulated physiological process that controls the BBB. The activation of PDGF-CC by tPA depends on interactions between the kringle-2 domains of the protease with the two domains in the PDGF-C polypeptide chain 100 as well as on binding to the coreceptor LRP. 15 This presumably ensures correct positioning of tPA and PDGF-CC enabling activation in close proximity to the PDGFR-α in the NVU and stimulation of increased cerebrovascular permeability. This is supported by the findings that desmoteplase, vampire bat-derived plasminogen activator, which lacks the kringle-2 domain, 101 and thus presumably interaction with PDGF-CC, has been shown to have no effect on inducing BBB permeability. 16 Taken together we propose that in physiologic conditions, tPA is released in response to neuronal activity into the perivascular space where it activates PDGF-CC, and subsequently PDGFR-α signaling on perivascular astrocytes, through interaction with LRP, which leads to cerebrovascular changes associated with neuronal activity (►Fig. 3A).
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It should be noted that the action of tPA on BBB regulation has also been reported to be mediated by plasmin and downstream mediators other than PDGF-CC, including plasmin-induced truncation of MCP1. 16, 99 In the case with MCP1, it was found that BBB integrity was compromised much later than that induced by PDGF-CC. Prolonged opening of the barrier will lead to changes in parenchymal homeostasis where blood-borne substances such as plasmin can enter the CSF and in turn cleave MCP1. In support of this hypothesis are our findings that early after barrier breach induced by PDGF-CC, no gross changes of vascular structures were noted, 15 whereas MCP1-induced opening was associated with disruption of tight junction proteins (occludin and ZO-1) and reorganization of the actin cytoskeleton.
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Furthermore, it has been postulated that the controversy regarding mechanisms mediating the role of tPA in BBB regulation may, at least in part, be due to the concentration of tPA. 70 Through several elaborate calculations and assumptions, the overall concentration of tPA in the brain 3 hours after an ischemic event has been proposed to be approximately 1 nM, and even lower during physiologic conditions. 70 Therefore, since the amounts of tPA often used in experimental settings could potentially result in tPA concentrations that are higher than this, it has been suggested that these potentially supraphysiologic concentrations might lead to nonphysiologic observations. 70 However, the actual endogenous concentration of tPA in the NVU is not known, and may in fact be significantly higher than the 1 nM suggested earlier. Indeed, the release of tPA from activated neurons and subsequent binding to cofactors, such as LRP, could generate very high local concentrations of tPA in the NVU, which could be underestimated when evaluating gross brain tissue extracts.
Pathophysiologic Roles of tPA in the CNS
It was quickly recognized that the physiologic roles of tPA in the CNS may also be involved in pathophysiological events observed in several neurological diseases including cerebral ischemia, head trauma, and seizures. 58 This led to a large number of in vitro and in vivo studies, but the role of tPA in pathology is still intensely debated and the literature is conflicted. The main controversy concerns the potential neuroprotective or neurotoxic functions of tPA in the CNS and what downstream mediators facilitate the response. Here, we discuss how these controversies might be explained by the early effect of tPA on cerebrovascular permeability. Interestingly, the role of tPA in BBB regulation highlights a commonality in neurovascular signaling events between diverse neurologic disorders and may potentially represent a previously overlooked therapeutic target for seemingly unrelated brain diseases.
Ischemic Stroke
Stroke is a leading cause of adult morbidity and mortality. 102 The most common form of stroke is ischemic stroke, which occurs when there is an abrupt interruption of blood flow to the brain. The finding that tPA specifically binds to, and is stimulated by, fibrin 103,104 led to the hypothesis that clot lysis (thrombolysis) using tPA would facilitate a localized activation of plasmin at the site of occlusion. This was successfully demonstrated early on 105 and today tPA is the only approved thrombolytic drug for treatment of acute ischemic stroke. 2 However, early animal studies advised against indiscriminate use of thrombolytic tPA in ischemic stroke, as it was reported to mediate neuronal damage or cerebral hemorrhage. 8,106-109 Consistent with these preclinical studies, thrombolysis with tPA in ischemic stroke patients carries a significant risk of intracerebral hemorrhage, 2,110-113 and due in part to this increased risk of hemorrhagic conversion it is estimated that only 5 to 7% of ischemic stroke patients receive intravenous tPA, with another 1 to 2% receiving intra-arterial therapy. 2, [114] [115] [116] [117] [118] [119] The mechanism by which thrombolytic tPA might lead to increased hemorrhagic transformation is not completely understood, but it appears to be due in part to unique activities of tPA in the CNS. This is supported by the findings that tPA activity rapidly increases in ischemic tissue in experimental models of ischemic stroke.
14,107,120
One of the first studies demonstrating that tPA can negatively affect outcome in an experimental model of middle cerebral artery occlusion (MCAO) showed that tPA À/À mice had significantly smaller cerebral infarcts than wild-type mice, and that intravenous administration of tPA to tPA À/À mice increased infarct volume to levels comparable to wildtype controls. 107 In support of this, it has been shown that neuroserpin, the primary inhibitor of tPA in the CNS,
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provided neuronal protection and reduced infarct volume during MCAO. 120, 121 Based on these studies, it was concluded that tPA has neurotoxic effects in the ischemic brain. It should, however, be noted that several conflicting studies have been published showing that loss of tPA is associated with increased lesion volume, 122 and conversely that increased levels of tPA, through intravenous administration of tPA to wild-type mice or transgenic overexpression of tPA in neurons of mice (T4), decreased infarct volume following MCAO. 29 This proposed a neuroprotective role of tPA during MCAO and the mechanism of action was ascribed to tPAinduced increase in GLUT3 expression followed by increased glucose uptake to meet the increased metabolic demand of cerebral cortical neurons. In line with this hypothesis, it was reported that the T4 transgenic mice that neuronally overexpress tPA displayed significant upregulation of GLUT3 protein expression in ischemic brain tissue and higher glucose uptake after MCAO. 29 However, it is somewhat difficult to reconcile these data because GLUT3 expression and glucose uptake were found to be decreased in wild-type mice after MCAO, despite an increased endogenous release of tPA during ischemia. 14,107,120 Thus, it is possible that, similar to the tPA À/ À mice, overexpression of tPA in the neurons of T4 mice is associated with some congenital cerebrovascular anomaly that has yet to be discovered. The mechanism by which tPA exerts neurotoxic effects has been postulated to be mediated through plasmin-independent cleavage of the NR1 subunit in NMDA receptor followed by enhanced signaling. 10 However, the direct cleavage of NR1 has later been questioned by other research groups who have suggested that the NMDA receptor is not a direct target of tPA proteolysis, although plasmin was found to be able to mediate cleavage of the NMDA receptor. 123, 124 Instead, as noted earlier, an alternative mechanism has emerged, suggesting that tPA-mediated changes in cerebrovascular permeability might be the underlying cause of the neurotoxic effects reported for tPA in the CNS. This was based on the discoveries that tPA increases permeability of the BBB both in rodents 14, 98 and in humans 125 following ischemic stroke. This is particularly interesting because BBB dysfunction is a hallmark of many neurologic diseases, including ischemic stroke 126 and it has been proposed that pathologic disruption of the barrier will lead to extravasation of blood-borne molecules such as fibrin(ogen) into the brain parenchyma, where it can trigger different cellular and molecular responses including a delayed inflammatory response.
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In one study, 14 it was demonstrated that tPA À/À mice were protected from early loss of BBB integrity after MCAO. This study further showed that the tPA-induced opening of the BBB was dependent on the proteolytic activity of tPA, but was independent of plasmin, thus indicating the existence of another tPA substrate. Since MMP-9 had been implicated as a downstream mediator of tPA in the CNS 59 and MMP-9 deletion in mice had been shown to reduce BBB permeability and infarct volume 24 hours after stroke, 128 this was initially thought to be responsible for the effect of tPA on the BBB. However, MMP-9-deficient mice were found to display BBB dysfunction similar to wild-type mice early (6 hours) after MCAO.
14 Furthermore, depletion of circulating leukocytes was found to completely block the rise in MMP-9 activity within the first 24 hours after ischemic stroke, 129 suggesting that the increased MMP-9 activity seen after ischemic stroke is likely due to infiltrating leukocytes. This is consistent with the findings that MMP-9 is not expressed in either neurons or astrocytes in the first 24 hours after ischemic stroke.
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Finally, it was also shown that treatment with recombinant tPA after transient MCAO exacerbates BBB disruption 24 hours later in both wild-type and MMP-9 knockout mice. 131 Collectively, these data suggest that MMP-9-mediated events occur on the luminal side of the NVU and are not involved in the early effects on BBB permeability mediated by tPA after ischemic stroke. The findings that tPA regulation of the BBB is mediated through plasmin-independent catalysis of PDGF-CC and subsequent activation of PDGFR-α on perivascular astrocytes (discussed earlier), and that blocking this pathway, either by neutralizing antibodies against PDGF-CC or with the PDGFR-α inhibitor imatinib, significantly reduced BBB permeability and hemorrhagic complications associated with thrombolytic tPA treatment suggested a potential treatment strategy to reduce the complications associated with thrombolytic tPA by inhibiting PDGFR-α signaling.
15 Support for the potential role of PDGF-CC in thrombolysis-associated complications in humans was provided by a study showing that PDGF-CC levels are increased in the plasma of ischemic stroke patients after thrombolytic tPA treatment and higher levels of PDGF-CC were associated with an increased risk of hemorrhagic transformation. 132 On the basis of these findings, a randomized controlled clinical trial has been conducted at the Karolinska University Hospital to assess the possibility of using imatinib as an adjuvant therapy with thrombolytic tPA and the outcome of this study is currently being evaluated (Istrokepilot, EudraCT Number: 2010-019014-25). It is thus possible that decreased energy and metabolic supply to neurons during ischemia leads to increased release of tPA into the NVU, where it, through activation of PDGF-CC/ PDGFR-α signaling, leads to increased BBB permeability (►Fig. 3B). However, excessive signaling leads to further opening of the barrier and subsequent extravasation of blood-borne substances from the vascular space into the brain parenchyma. Following intravenous treatment with thrombolytic tPA, it is plausible that exogenous tPA enters the brain through the breached BBB, thereby exacerbating the PDGF-CC/PDGFR-α signaling in the NVU. This might eventually cause complete disruption of the BBB, consequently resulting in hemorrhagic complications. It should be noted that thrombolytic therapy with tPA in patients with pulmonary embolism, deep vein thrombosis, or myocardial infarction also carries an approximately 1 to 1.5% risk of symptomatic intracerebral hemorrhage, 133, 134 suggesting that even without cerebral ischemia exogenous tPA can induce BBB opening and promote hemorrhage. This is also supported by the fact that intravenously administered tPA can cross the intact barrier and slightly increase BBB permeability in naive rats.
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Interestingly, tPA-catalyzed activation of PDGF-CC/PDGFR-α signaling can also induce BBB permeability and contribute to disease progression in several other experimental models of neurologic disease including TBI, 136 seizures, 20 and amyotrophic lateral sclerosis 137 (discussed later).
Traumatic Brain Injury
The broadening role of tPA in the regulation of BBB permeability in ischemic stroke raised the question of its role in other CNS pathologies. In the case of TBI, BBB disruption is a serious consequence which plays a major role in the promotion of cerebral edema and increases in intracranial pressure: two devastating clinical manifestations of TBI that contribute to the high level of mortality and morbidity postinjury, and for which there are scant therapeutic options. 138 Although ischemic stroke and TBI have vastly different initiating stimuli, there was a clear rationale to explore the role of tPA in the promotion of BBB permeability following TBI. Endogenous tPA, as well as most other components of the plasminogen-activating system including plasminogen and PAI-1, is not only expressed in various compartments of the brain, they can also be induced following various stimuli, including glutamate analogs. 51, 139, 140 As levels of excitotoxic amino acids are known to increase in the damaged brain following TBI,
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it stood to reason that this would promote increases in the levels of endogenous tPA following TBI and that this in turn would influence outcome and recovery. Initial support for a detrimental role for tPA post-TBI was provided in a study in 2001, where it was shown that tPA-deficient mice had less edema and improved recovery in a model of TBI. 109 It was also shown in separate publications that administration of tPA to pigs subjected to TBI resulted in an increase in brain water content. 142 A later publication from the same group linked this effect of tPA to increased vasodilatation and activation of mitogen-activated protein kinase. 143 Although none of these studies specifically investigated tPA-mediated changes in BBB permeability following TBI, these results were certainly consistent with this possibility.
Direct evidence that levels of tPA activity were indeed upregulated following TBI, and tPA has a major influence on BBB permeability following TBI, was provided in 2011 and 2012. Sashindranath et al used a modified amidolytic assay to show that endogenous levels of tPA activity were transiently increased in the cortex following TBI.
144 tPA activity increased approximately 25% within 1 hour of TBI and this increase was maintained at 3 hours postinjury but reduced to preinjury levels by 24 hours. A subsequent study from the same group compared the extent of BBB permeability in wildtype and tPA À/À mice following TBI using the Evan's blue brain extravasation assay. 145 Wild-type mice were shown to have marked increase in BBB permeability when assessed 3 hours post-TBI; however, this was not seen in tPA À/À mice, thereby implicating endogenous tPA in this process. Importantly, tPA À/À mice also had improved neurological outcome following TBI. On the other hand, transgenic mice with neuronal overexpression of tPA (T4 mice, described earlier) displayed enhanced BBB permeability and a more severe neurological phenotype post-TBI. Hence, tPA expression was causally linked with BBB permeability following TBI, with the absence of tPA being protective, and increased levels being deleterious in TBI, reminiscent of the results seen in earlier studies in mouse models of ischemic stroke. An interesting observation arising from this study concerned the mechanism by which tPA was promoting BBB permeability following TBI. It was assumed that tPA was promoting parenchymal extravasation following TBI via its proteolytic capacity, either via plasmin generation or via different substrates (i.e., PDGF-CC). It was anticipated that inhibition of endogenous tPA would recapitulate the protective phenotype seen when tPA À/À mice was subjected to TBI.
The approach used by these authors was to inhibit local tPA activity within the lesion of the brain immediately following TBI by stereotactic injection of PAI-1. This approach indeed inhibited levels of endogenous tPA activity greater than 90% as determined using an amidolytic assay. 145 However, in stark contrast to expectations, the blocking effect of PAI-1 against tPA actually resulted in an increase in extravasation 3 hours postinjury. This puzzling result was eventually explained when the authors investigated the downstream consequences of complexes formed between tPA and PAI-1. It has been known for decades that tPA:PAI-1 complexes (and indeed many other serpin:protease inhibitor complexes) are cleared from plasma and the extravascular space by member of the LDL receptor family. 146, 147 It had also been reported that LDL receptor family members could modulate activity of integrins and receptor tyrosine kinases that in turn can initiate intracellular signaling. 148 Speculation therefore arose that the introduction of PAI-1 into the damaged brain following TBI, despite blocking endogenous tPA activity, was initiating an unanticipated signal through LDL receptors via the formation of tPA:PAI-1 complexes. Support for this notion was provided from several lines of evidence; first, coinjection of the LDL receptor family antagonist, RAP with PAI-1, blocked the increase in extravasation; second, stereotactic injection of PAI-1 into tPA À/À mice had no effect at promoting extravasation post-TBI; third, coinjection of a PAI-1 mutant that poorly 136 Of further note in this study was the finding of PDGF-CC in the cerebrospinal fluid of patients with TBI, with PDGF-CC levels positively correlating with injury severity. Hence, although at first glance it appears that tPA modulates BBB permeability via two different mechanisms in TBI (i.e., active tPA or inactive tPA:PAI-1 complexes), it may as well be that these differences relate to a temporal order of events. We speculate that the initial increase in BBB permeability during TBI is mediated by proteolytic-active tPA, potentially in response to the increased energy and metabolic demand in neurons following insult, and that excessive signaling leads to further opening of the barrier and subsequent increase in PAI-1 levels (through upregulated expression in response to the injury as well as increased extravasation from the vascular space into the brain parenchyma). This in turn leads to the formation of tPA:PAI-1 complexes that can exacerbate opening of the BBB, eventually causing disruption of the BBB and leakage of harmful blood-borne substances into the brain after TBI (►Fig. 3). It remains to be determined whether tPA:PAI-1 complex-mediated increase in BBB permeability also occurs in ischemic stroke, but this is worth investigating. Nonetheless, whatever the mechanism these findings have provided novel opportunities to minimize BBB opening following TBI and in doing so reduce the devastating complications of cerebral edema and the rise in intracranial pressure, thus demonstrating clear translational possibilities of these findings.
Seizures
The first evidence that tPA is important in the development of seizures came from studies in mice showing that tPA expression is increased early after seizures 36 and that tPA ablation leads to a higher threshold for seizures, 8, 149 whereas neuronal overexpression leads to a lower seizure threshold. 150 The relationship between tPA and seizures in humans is less well understood, but a recent study has described a positive correlation between increased serum tPA levels and epilepsy severity in children with idiopathic and intractable epilepsies. 151 The mechanism by which tPA affects seizures is not fully established, but tPA has been suggested to act directly on neuronal cells by cleavage of the NMDA receptor, 10 or indirectly by altering cerebrovascular permeability. 20 The latter is supported by the fact that impaired integrity of the BBB is a well-known feature of seizures, although it is debated whether impaired BBB function is just a consequence of seizure activity or a contributor to seizure progression.
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However, since 30% of individuals with seizures fail to respond to existing treatments, 152 recent studies have begun to consider the cerebrovasculature as a potential avenue for therapeutic intervention.
20,153-156
The seminal observation illustrating that tPA À/À mice are resistant to excitotoxin-induced neuronal death and seizures after intrahippocampal injection of excitotoxins, including the glutamate analog kainic acid (KA), led to the conclusion that, in pathologic conditions, tPA has neurotoxic properties.
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Using a different experimental paradigm, where seizures were induced by injection of KA into the amygdala, other researchers were later able to confirm these results. 149 The fact that KA was not injected directly into the hippocampus allowed these researchers to dissect KA-induced, from seizure-induced, hippocampal neuronal death, yet genetic deficiency of tPA was associated with slower progression of KA-induced seizure activity throughout the limbic system and a decrease in seizures-induced hippocampal cell death.
To study the effect of tPA on excitotoxin-induced neuronal death without the confounding effect of seizures, a group of researchers injected NMDA, another glutamate analog, into the striatum of mice followed by intravenous treatment with tPA. 157 The advantage of this model is that the injection of NMDA into the striatum does not induce seizures. Using this approach, these investigators found that intravenous administration of tPA increases the volume of the necrotic lesion caused by the injection of NMDA. 157 Interestingly, glutamate has been shown to induce BBB permeability, 158 suggesting that following NMDA injection, the BBB may be more permeable, thus enabling intravenous tPA to extravasate into the brain parenchyma and further disrupt the barrier integrity. In line with this, a recent study illustrated that tPA regulated seizure progression primarily through control of the NVU and BBB integrity, and not through direct effects of tPA on neuronal activity. 20 This was supported by multiple independent experimental results, including the observation that increasing BBB permeability in seizure-resistant tPA À/À mice dramatically enhanced the rate of seizure progression, while interventions that maintain BBB integrity delayed seizure propagation. In addition, the comparison of in vivo EEG recordings to ex vivo hippocampal electrophysiological recordings demonstrates that the phenotypic differences in seizure progression noticed between wild-type (intermediate), tPA À/À (protected), and neuroserpin-deficient mice (enhanced) in vivo were absent in ex vivo studies, where BBB regulation is no longer important for maintenance of the extracellular environment. As seen in ischemic stroke and TBI, the effect of tPA on BBB permeability in seizures was illustrated to be facilitated, at least in part, through PDGF-CCinduced activation of PDGFR-α signaling in perivascular astrocytes, which is of particular interest because earlier reports have suggested astrocytes to play a central role in the pathology of seizures.
Conclusion
It is well appreciated that tPA is controlling unique functions within the CNS, distinct from its role in fibrinolysis, although the downstream targets mediating these functions and the suggested outcome ascribed to tPA activity in the CNS are many and intensely debated. Here, we summarize the existing evidence in support of the hypothesis that the neurovascular events regulated by tPA might provide a unifying pathway for many of the pleiotropic effects of tPA in the CNS. The essential take-home messages from this review are as follows:
• tPA is highly expressed in the CNS.
• The role of tPA in the CNS is very different from its role in fibrinolysis within the vascular space.
• tPA is reported to have many pleiotropic activities in the CNS, mediated through several various downstream substrates.
• Here, we propose that the neurovascular events regulated by tPA might provide a unifying pathway for many of the pleiotropic effects of tPA in the CNS.
